Tag-72, CA 19.9 and CEA as Tumor Markers in Gastric Cancer

References

• La Vecchia C, Lucchini F, Negri E, Boyle P, Maisonneuve P, Levi F. Trends of cancer mortality in Europe, 1955–1989: I. Digestive sites. Eur J Cancer 1992; 28: 132–5
   PubMed Web of Science ®Google Scholar
• Waldman T A, Heberman R H. Tumor markers in diagnosis and in monitoring therapy. Cancer medicine, J F Holland, E Frei. Lea & Febiger, Philadelphia 1982; 1068–89
   Google Scholar
• Klavins J V. Tumor markers. Clinical and laboratory studies. Alan R Liss, New York 1985
   Google Scholar
• Bates S E. Clinical applications of serum tumor markers. Ann Intern Med 1991; 115: 623–38
   PubMed Web of Science ®Google Scholar
• Heptner G, Domschke S, Domschke W. Comparison of CA 72–4 with CA 19–9 in the serodiagnostics of gastrointestinal malignancies. Scand J Gastroenterol 1989; 24: 745–50
   PubMed Web of Science ®Google Scholar
• Byrne D J, Browning M CK, Cuschieri A. CA 72.4: a new tumour marker for gastric cancer. Br J Surg 1990; 77: 1010–3
   PubMed Web of Science ®Google Scholar
• Guadagni F, Roselli M, Amato T, et al. CA 72–4 measurement of tumor-associated glycoprotein 72 (TAG-72) as a serum marker in the management of gastric carcinoma. Cancer Res 1992; 52: 1222–7
   PubMed Web of Science ®Google Scholar
• Ychou M, Tuszinski T, Pignon J P, et al. Adenocarcinomes gastriques: comparaison du CA 19–9 et de l'antigène carcinoembryonnaire pour le diagnostic des récidives après traitement chirurgical. Gastroenterol Clin Biol 1992; 16: 848–52
   PubMedGoogle Scholar
• Hamazoe R, Maeta M, Matsui T, Shibata S, Shiota S, Kaibara N. CA 72–4 compared with carcinoembryonic antigen as a tumour marker for gastric cancer. Eur J Cancer 1992; 28A: 1351–4
   PubMed Web of Science ®Google Scholar
• Wobbes T, Thomas C M, Segers M F, Nagengast F M. Evaluation of seven tumor markers (CA 50, CA 19–9, CA 19–9 truQuant, CA 72–4, CA 195, carcinoembryonic antigen, and tissue polypeptide antigen) in the pretreatment sera of patients with gastric carcinoma. Cancer 1992; 69: 2036–41
   PubMed Web of Science ®Google Scholar
• Norton J A. Carcinoembryonic antigen. New applications for an old marker. Ann Surg 1991; 213: 95–7
   PubMed Web of Science ®Google Scholar
• Del Villano B C, Brennan S, Brock P, et al. Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19–9. Clin Chem 1983; 29: 549–52
   PubMed Web of Science ®Google Scholar
• Filella X, Molina R, Grau J J, et al. Prognostic value of CA 19.9 levels in colorectal cancer. Ann Surg 1992; 216: 55–9
   PubMed Web of Science ®Google Scholar
• Colcher D, Horan Hand P, Nuti M, Schlom J. A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci USA 1981; 78: 3199–203
   PubMed Web of Science ®Google Scholar
• Klug T L, Sattler M A, Colcher D, Schlom J. Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 72) on a novel pancarcinoma antigen (TAG-72). Int J Cancer 1986; 38: 661–9
   PubMed Web of Science ®Google Scholar
• Filella X, Molina R, Jo J, Bedini J L, Joseph J, Ballesta A M. Tumor associated glycoprotein-72 (TAG-72) levels in patients with non-malignant and malignant disease. Bull Cancer 1992; 79: 271–7
   PubMed Web of Science ®Google Scholar
• Loewenstein M S, Zamcheck N. Carcinoembryonic antigen (CEA) levels in benign gastrointestinal disease. Cancer 1978; 42: 1412–8
   PubMed Web of Science ®Google Scholar
• Barone D, Onetto M, Conio M, et al. CA 19.9 assay in patients with extrahepatic cholestatic jaundice. Int J Biol Markers 1988; 3: 95–100
   PubMedGoogle Scholar
• Cases A, Filella X, Molina R, et al. Tumor markers in chronic renal failure and hemodialysis patients. Nephron 1991; 57: 183–6
   PubMed Web of Science ®Google Scholar
• Thor A, Ohuchi N, Szpak C A, Johnston W W, Schlom J. Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res 1986; 46: 3118–24
   PubMed Web of Science ®Google Scholar
• Staab H J, Anderer F A, Stumpf E, Hornung A, Fischer R, Kieninger G. Eighty-four potential second-look operations based on sequential carcinoembryonic antigen determinations and clinical investigations in patients with recurrent gastrointestinal cancer. Am J Surg 1985; 149: 198–201
   PubMed Web of Science ®Google Scholar